Drug network identification predicts injecting risk behavior among people who inject drugs on hepatitis C virus treatment in Tayside, Scotland

The risk of Hepatitis C Virus (HCV) acquisition among People Who Inject Drugs (PWID) remains high when injecting risk behavior within networks endures. Several psychosocial factors influence such behavior. Following a drive within Tayside, a geographic region in Scotland, to achieve World Health Organization HCV elimination targets, addressing HCV re-infection risk as a barrier to elimination is critically important. This cross-sectional study seeks to address this barrier to elimination by investigating associations between group identification (one's subjective sense of belonging and connectedness to a social group coupled with a sense of shared goals, beliefs and values with the other members of the group) and injecting risk behavior among PWID on HCV treatment at needle and syringe provision sites in Tayside. Participants completed psychosocial questionnaires between treatment weeks zero and three of treatment. Correlation analyses were undertaken, and significant factors included in multiple linear regression models for injecting risk behavior. Injecting frequency, drug network identification, and family identification, were correlated with injecting risk behavior, and drug network identification had a positive predictive on injecting risk behavior. Identification with a social group, conventionally associated with improved health, may pose health risks in specific contexts. Healthcare providers should consider stratifying individuals with higher group identification with PWID networks for enhanced harm reduction engagement to mitigate transmissible infection risk among PWID. Additionally, psychological interventions to strengthen group identification with networks which impact positively on health behavior should be explored.

[1]  C. Treloar,et al.  Peer-facilitated treatment access for hepatitis C: the Live Hep C Free project , 2022, Harm Reduction Journal.

[2]  S. Hutchinson,et al.  Real‐world outcomes of rapid regional hepatitis C virus treatment scale‐up among people who inject drugs in Tayside, Scotland , 2021, Alimentary pharmacology & therapeutics.

[3]  P. Hayes,et al.  Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs , 2021, Journal of hepatology.

[4]  E. Cama,et al.  Positive effects of community attachment on internalised stigma and wellbeing among people who inject drugs. , 2021, The International journal on drug policy.

[5]  H. E. Ahmad,et al.  Assessment of anxiety and depression among substance use disorder patients: a case-control study , 2020, Middle East Current Psychiatry.

[6]  C. Strike,et al.  'It's too much, I'm getting really tired of it': Overdose response and structural vulnerabilities among harm reduction workers in community settings. , 2019, The International journal on drug policy.

[7]  N. Luhmann,et al.  We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade , 2019, Journal of internal medicine.

[8]  L. Brener,et al.  Care, agency and criminality: Making sense of authorised extended distribution in the accounts of key stakeholders. , 2019, The International journal on drug policy.

[9]  F. Sani,et al.  Change in injecting behaviour among people treated for hepatitis C virus: The role of intimate partnerships , 2018, Journal of viral hepatitis.

[10]  J. Leung,et al.  Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs , 2018, Addiction.

[11]  G. Dingle,et al.  The New Psychology of Health: Unlocking the Social Cure , 2018, Clinical Psychology Forum.

[12]  Atte Oksanen,et al.  Addictive behaviors and psychological distress among adolescents and emerging adults: A mediating role of peer group identification , 2018, Addictive behaviors reports.

[13]  C. Latkin,et al.  Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era , 2018, Journal of viral hepatitis.

[14]  Mark S. Edwards,et al.  Illness Perceptions, Coping, Benefit Finding, and Adjustment in Individuals with Hepatitis C , 2018 .

[15]  C. Treloar,et al.  Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting. , 2018, Drug and alcohol dependence.

[16]  C. von Hippel,et al.  Implicit and explicit internalized stigma: Relationship with risky behaviors, psychosocial functioning and healthcare access among people who inject drugs. , 2018, Addictive behaviors.

[17]  Mark S. Edwards,et al.  The Self-Regulatory Model of Illness and Adjustment Outcomes in Hepatitis C , 2017 .

[18]  S. Fraser,et al.  "Don't think I'm going to leave you over it": Accounts of changing hepatitis C status among couples who inject drugs. , 2017, Drug and alcohol dependence.

[19]  S. Fraser,et al.  Hepatitis C prevention and convenience: why do people who inject drugs in sexual partnerships ‘run out’ of sterile equipment? , 2016 .

[20]  Michael A. Jenkins-Guarnieri,et al.  The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5): Development and Evaluation Within a Veteran Primary Care Sample , 2016, Journal of General Internal Medicine.

[21]  P. Pattison,et al.  Hepatitis C transmission and treatment as prevention - The role of the injecting network. , 2015, The International journal on drug policy.

[22]  F. Sani,et al.  Greater number of group identifications is associated with healthier behaviour: Evidence from a Scottish community sample. , 2015, British journal of health psychology.

[23]  F. Sani,et al.  Greater number of group identifications is associated with lower odds of being depressed: evidence from a Scottish community sample , 2015, Social Psychiatry and Psychiatric Epidemiology.

[24]  G. E. Harris,et al.  Peering into the literature: A systematic review of the roles of people who inject drugs in harm reduction initiatives. , 2015, Drug and alcohol dependence.

[25]  C. Shapiro,et al.  The importance of fatigue cognitions in chronic hepatitis C infection. , 2015, Journal of psychosomatic research.

[26]  M. Newman,et al.  Delay discounting and the use of mindful attention versus distraction in the treatment of drug addiction: a conceptual review. , 2015, Journal of the experimental analysis of behavior.

[27]  P. Pattison,et al.  The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs , 2014, Hepatology.

[28]  G. Donenberg,et al.  Psychiatric correlates of injection risk behavior among young people who inject drugs. , 2014, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors.

[29]  G. Dingle,et al.  Depression and Social Identity , 2014, Personality and social psychology review : an official journal of the Society for Personality and Social Psychology, Inc.

[30]  P. Sedgwick Cross sectional studies: advantages and disadvantages , 2014, BMJ : British Medical Journal.

[31]  R. Heimer,et al.  Associations Between Injection Risk and Community Disadvantage Among Suburban Injection Drug Users in Southwestern Connecticut, USA , 2014, AIDS and Behavior.

[32]  T. Rhodes,et al.  Hepatitis C Avoidance in Injection Drug Users: A Typology of Possible Protective Practices , 2013, PloS one.

[33]  M. Cano,et al.  Injecting transition risk and depression among Mexican American non-injecting heroin users. , 2012, Drug and alcohol dependence.

[34]  E. Wood,et al.  The Injection Support Team: A Peer-Driven Program to Address Unsafe Injecting in a Canadian Setting , 2012, Substance use & misuse.

[35]  E. Robles,et al.  Delay discounting, impulsiveness, and addiction severity in opioid-dependent patients. , 2011, Journal of substance abuse treatment.

[36]  C. Latkin,et al.  The relationship between social network factors, HIV, and Hepatitis C among injection drug users in Chennai, India. , 2011, Drug and alcohol dependence.

[37]  R. Bruno,et al.  Transition to and from injecting drug use among regular ecstasy users. , 2010, Addictive behaviors.

[38]  L. Palinkas,et al.  The perceived consequences of safer injection: An exploration of qualitative findings and gender differences , 2010, Psychology, health & medicine.

[39]  E. Wood,et al.  Social structural factors that shape assisted injecting practices among injection drug users in Vancouver, Canada: a qualitative study , 2010, Harm reduction journal.

[40]  L. Ouellet,et al.  Prevalence and Correlates of Former Injection Drug Use Among Young Noninjecting Heroin Users in Chicago , 2010, Substance use & misuse.

[41]  Sudirman Nasir,et al.  The social context of initiation into injecting drugs in the slums of Makassar, Indonesia. , 2009, The International journal on drug policy.

[42]  M. Bloor,et al.  Theorising equipment-sharing in a cohort of Scottish drug users , 2008 .

[43]  R. Garfein,et al.  Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five U.S. cities. , 2007, Drug and alcohol dependence.

[44]  J. Wylie,et al.  Determinants of injection drug user (IDU) syringe sharing: the relationship between availability of syringes and risk network member characteristics in Winnipeg, Canada. , 2007, Addiction.

[45]  R. Platt,et al.  Social Network-Related Risk Factors for Bloodborne Virus Infections Among Injection Drug Users Receiving Syringes through Secondary Exchange , 2007, Journal of Urban Health.

[46]  J. Hyde,et al.  Needle-sharing among young IV drug users and their social network members: The influence of the injection partner's characteristics on HIV risk behavior. , 2006, Addictive behaviors.

[47]  Elizabeth Broadbent,et al.  The brief illness perception questionnaire. , 2006, Journal of psychosomatic research.

[48]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[49]  Don C Des Jarlais,et al.  Transitions to Injecting Drug Use Among Noninjecting Heroin Users: Social Network Influence and Individual Susceptibility , 2006, Journal of acquired immune deficiency syndromes.

[50]  J. Marsden,et al.  Reduced injection risk and sexual risk behaviours after drug misuse treatment: Results from the National Treatment Outcome Research Study , 2002, AIDS care.

[51]  R. Spitzer,et al.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. , 1999, JAMA.

[52]  G. Stimson,et al.  A short questionnaire (IRQ) to assess injecting risk behaviour. , 1998, Addiction.

[53]  J. Fountain,et al.  Continuing drug risk behaviour: shared use of injecting paraphernalia among London heroin injectors. , 1997, AIDS care.